Your browser is no longer supported. Please, upgrade your browser.
Settings
GRFS [NASD]
Grifols, S.A.
Index- P/E21.94 EPS (ttm)0.49 Insider Own- Shs Outstand985.19M Perf Week-8.13%
Market Cap10.57B Forward P/E9.02 EPS next Y1.19 Insider Trans- Shs Float300.94M Perf Month-18.15%
Income- PEG1.91 EPS next Q0.30 Inst Own43.00% Short Float1.45% Perf Quarter-25.95%
Sales5.23B P/S2.02 EPS this Y-10.00% Inst Trans0.10% Short Ratio6.37 Perf Half Y-38.51%
Book/sh3.96 P/B2.71 EPS next Y20.81% ROA- Target Price35.26 Perf Year-42.09%
Cash/sh0.00 P/C- EPS next 5Y11.50% ROE- 52W Range10.48 - 20.49 Perf YTD-41.81%
Dividend0.91 P/FCF- EPS past 5Y2.78% ROI- 52W High-47.90% Beta0.43
Dividend %8.48% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low1.86% ATR0.36
Employees24000 Current Ratio- Sales Q/Q-8.40% Oper. Margin- RSI (14)24.66 Volatility3.34% 2.69%
OptionableYes Debt/Eq- EPS Q/Q-30.30% Profit Margin- Rel Volume1.33 Prev Close10.73
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume684.76K Price10.68
Recom2.00 SMA20-10.95% SMA50-20.31% SMA200-32.20% Volume682,669 Change-0.51%
Nov-05-21Downgrade Deutsche Bank Buy → Hold
Oct-19-21Downgrade Barclays Overweight → Underweight
Oct-06-21Upgrade Citigroup Neutral → Buy
Jun-14-21Upgrade Deutsche Bank Hold → Buy
Apr-20-21Initiated Deutsche Bank Hold
Mar-23-21Upgrade Credit Suisse Neutral → Outperform
Mar-11-21Upgrade HSBC Securities Hold → Buy
Oct-01-20Upgrade Citigroup Sell → Neutral
Jun-09-20Upgrade HSBC Securities Reduce → Hold
Jun-09-20Downgrade Citigroup Neutral → Sell
Mar-25-20Downgrade Citigroup Buy → Neutral
Jun-27-19Upgrade JP Morgan Neutral → Overweight
Feb-08-19Downgrade Berenberg Buy → Hold
Oct-11-18Upgrade Berenberg Hold → Buy
Jun-01-18Initiated Barclays Overweight
Oct-31-17Initiated Citigroup Buy
Jun-30-17Downgrade Goldman Buy → Neutral
Apr-06-17Initiated BofA/Merrill Buy
Jan-03-17Upgrade JP Morgan Neutral → Overweight
Feb-09-16Upgrade Berenberg Hold → Buy
Nov-30-21 09:00AM  
Nov-05-21 08:05AM  
Nov-04-21 09:00AM  
Oct-19-21 11:21AM  
11:18AM  
Sep-17-21 03:57AM  
03:15AM  
Aug-11-21 10:26AM  
Jul-28-21 08:00AM  
Jul-14-21 10:00AM  
06:08AM  
Jun-02-21 11:00PM  
Jun-01-21 10:30AM  
May-25-21 10:15AM  
May-19-21 05:30AM  
Apr-28-21 06:44AM  
Apr-15-21 11:59AM  
09:00AM  
Apr-09-21 10:30AM  
Apr-02-21 11:18AM  
Mar-25-21 06:00AM  
Mar-23-21 10:00AM  
Mar-22-21 09:00AM  
Mar-18-21 06:00AM  
Mar-09-21 03:15AM  
Mar-08-21 01:00PM  
09:15AM  
07:33AM  
07:00AM  
Feb-23-21 09:00AM  
Feb-16-21 09:00AM  
Feb-04-21 11:50AM  
Feb-03-21 11:40AM  
Jan-28-21 08:00AM  
Jan-25-21 10:34AM  
Jan-22-21 09:51AM  
Jan-19-21 09:02AM  
Jan-18-21 06:00AM  
Jan-12-21 11:40AM  
Dec-16-20 10:21PM  
Nov-24-20 10:16AM  
Nov-20-20 11:57AM  
Nov-16-20 09:19AM  
09:14AM  
06:01AM  
Nov-12-20 09:00AM  
Nov-06-20 03:01PM  
Nov-04-20 02:28PM  
Nov-02-20 07:35AM  
Oct-28-20 11:40AM  
10:58AM  
Oct-09-20 05:30AM  
Oct-07-20 12:45PM  
Oct-01-20 12:13PM  
Sep-08-20 10:46AM  
02:17AM  
Sep-07-20 02:50AM  
Aug-10-20 04:00PM  
Aug-05-20 06:04PM  
02:01AM  
Jul-28-20 10:41AM  
Jul-27-20 01:18PM  
Jul-23-20 08:00AM  
Jul-20-20 07:39AM  
02:55AM  
02:39AM  
02:36AM  
Jul-17-20 12:45PM  
Jul-09-20 03:57PM  
08:19AM  
Jun-30-20 11:18AM  
Jun-24-20 04:22AM  
Jun-19-20 01:12AM  
Jun-12-20 11:54AM  
Jun-11-20 08:12AM  
04:03AM  
May-26-20 09:00AM  
May-07-20 12:06PM  
09:00AM  
Apr-28-20 09:00AM  
Apr-27-20 11:40AM  
Apr-20-20 02:53PM  
09:00AM  
01:27AM  
Apr-09-20 11:40AM  
Apr-06-20 09:30AM  
Mar-31-20 10:12AM  
Mar-26-20 08:23AM  
Mar-25-20 05:25PM  
03:55PM  
Mar-21-20 12:52PM  
Mar-18-20 11:48AM  
Mar-05-20 12:00PM  
09:34AM  
Feb-27-20 11:40AM  
Feb-21-20 07:52AM  
Feb-19-20 07:21AM  
Feb-18-20 07:37AM  
Feb-13-20 09:00AM  
Feb-11-20 11:40AM  
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.